NCT05791799

Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus

A Multicenter Prospective Randomized Controlled Clinical Study of Etonogestrel Implants to Protect Ovarian Reserve Function in Systemic Lupus Erythematosus

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
• Sex: Female
• Age: 18 Years – 37 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial aims to test in female patients with systemic lupus erythematosus (SLE). The main question it seeks to answer is whether etonogestrel implants can protect ovarian reserve function in patients with SLE. Participants will be randomly divided into a test group and a control group. The test group will be implanted subcutaneously with etongestrel for one year. Researchers won't intervene in the control group. After three months of drug-eluting, researchers will compare measures of ovarian reserve function in the test and control groups to see if etonogestrel implants can protect ovarian reserve function in patients with SLE.

Conditions

• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	Etonogestrel	Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year

Timeline

• Start date: 2023-04-01
• Primary completion: 2025-10-31
• Completion: 2025-10-31
• First posted: 2023-03-30
• Last updated: 2023-03-30